Please use this identifier to cite or link to this item:
|Title:||HIV decision support : from molecule to man||Authors:||Sloot, Peter M. A.
Coveney, P. V.
Boucher, Charles A. B.
|Keywords:||DRNTU::Science::Medicine::Computer applications||Issue Date:||2009||Source:||Sloot, P. M. A., Coveney, P. V., Ertaylan, G., Muller, V., Boucher, C., & Bubak, M. (2009). HIV decision support : from molecule to man. Philosophical transactions of the Royal Society A : mathematical, physical and engineering sciences, 367(1898), 2691-2703.||Series/Report no.:||Philosophical transactions of the Royal Society A : mathematical, physical and engineering sciences||Abstract:||Human immunodeficiency virus (HIV) is recognized to be one of the most destructive pandemics in recorded history. Effective highly active antiretroviral therapy and the availability of genetic screening of patient virus data have led to sustained viral suppression and higher life expectancy in patients who have been infected with HIV. The sheer complexity of the disease stems from the multiscale and highly dynamic nature of the system under study. The complete cascade from genome, proteome, metabolome and physiome to health forms a multidimensional system that crosses many orders of magnitude in temporal and spatial scales. Understanding, quantifying and handling this complexity is one of the biggest challenges of our time, which requires a highly multidisciplinary approach. In order to supply researchers with an interactive framework and to provide the medical professional with appropriate tools and information for making a balanced and reliable clinical decision, we have developed ‘ViroLab’, a collaborative decision-support system (http://www.virolab.org/). ViroLab contains computational models that cover various spatial and temporal scales from atomic-level interactions in nanoseconds up to sociological interactions on the epidemiological level, spanning years of disease progression. ViroLab allows for personalized drug ranking. It is on trial in six hospitals and various virology and epidemiology laboratories across Europe.||URI:||https://hdl.handle.net/10356/96522
|DOI:||http://dx.doi.org/10.1098/rsta.2009.0043||Rights:||© 2009 The Royal Society. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SCSE Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.